logo

For the Inventor, By the Inventor

Therwil, Switzerland

Jean-Michel Bastian

This inventor holds 16 USPTO granted patents. Top assignee: Sandoz Gmbh. Active years: 1976-1981.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Michel Bastian. Retrieved from https://idiyas.com/inventor/jean-michel-bastian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16

% Patents Active = 100.0

Average Co-Inventor Count = 1.3

ph-index = 4

Forward Citations = 47(Granted Patents)


Company Filing History:

goldMedal16 out of 1,603 
 
Sandoz Gmbh
 patents

Years Active: 1976-1981

Loading Chart...
16 patents (USPTO):Explore Patents
1. 4273780 - Anti-allergic (1981-06-16),
2. 4223035 - Treating prostate hypertrophy with (1980-09-16),
3. 4183943 - Organic compounds (1980-01-15),
4. 4150136 - Benz[g]isoquinolines and use thereof (1979-04-17),
5. 4144337 - 1,4-Substituted piperazinyl derivatives useful as psychostimulants (1979-03-13),
6. 4137323 - Organic compounds (1979-01-30),
7. 4081543 - 5-Substituted-1,2,3,4-tetrahydrobenzo[g]isoquinolines (1978-03-28),
8. 4072756 - Tricyclo piperidino ketones and soporific compositions thereof (1978-02-07),
9. 4052412 - Benzo cycloheptathiophene carboxylic acid derivatives (1977-10-04),
10. 4034095 - Benzo[5,6]cyclohepta[1,2-c]pyridines (1977-07-05),
11. 4032640 - 4H-Benzo[4,5]cyclohepta[1,2-b]thiophenes (1977-06-28),
12. 4031225 - 4H-Benzo[4,5]cyclohepta[1,2-b]thiophenes (1977-06-21),
13. 4024266 - 4H-Benzo[4,5]cyclohepta[1,2-b]thiophenes (1977-05-17),
14. 4024265 - Benzo[5,6]cyclohepta[1,2-c]pyridines (1977-05-17),
15. 3991066 - 1,3,4,9B-Tetrahydro-5-methyl-2H-indeno[1,2-c]pyridines (1976-11-09),

Title: Inventor Jean-Michel Bastian: Innovations in Allergy and Prostate Treatments

Introduction

Jean-Michel Bastian is a prominent inventor based in Therwil, Switzerland, recognized for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 16 patents, Bastian's work focuses primarily on novel treatments for allergic conditions and prostate hypertrophy.

Latest Patents

Among his latest inventions, Bastian developed an anti-allergic compound identified as anti-9,10-dihydro-4-(1-methyl-4-piperidylidene)-4H-benzo[4,5]-cyclohepta[1,2-b]thiophen-10(9H)-one oxime. This innovative formulation is designed to offer effective treatment options for various allergic conditions. Additionally, Bastian has been active in addressing prostate hypertrophy with a new compound, featuring distinct chemical compositions that may include hydrogen, chlorine, or lower alkyl groups, thereby expanding treatment avenues for this prevalent health issue.

Career Highlights

Bastian's enduring commitment to research and innovation has been instrumental in advancing the medical field. His affiliation with Sandoz GmbH showcases his professional dedication to creating solutions that tackle complex health challenges. Bastian’s contributions have helped shape the landscape of modern medicine, making potent therapeutic options more accessible to patients.

Collaborations

Throughout his career, Jean-Michel Bastian has collaborated with esteemed colleagues such as Anton Ebnother and Fulvio Gadient. These partnerships highlight the importance of teamwork in driving forward innovative research and bringing new inventions to fruition.

Conclusion

In summary, Jean-Michel Bastian stands out as a leading inventor in Therwil, Switzerland, with a focus on developing groundbreaking treatments for allergies and prostate issues. His impressive patent portfolio and collaborative efforts continue to influence the pharmaceutical industry significantly. Bastian's work exemplifies the spirit of innovation that drives advancements in health and wellness.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…